Agenus Inc
AGEN
NASDAQ
Biotechnology
$7.32
USD
+0.32 (+4.57%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $315.14M
Volume 1.3M
Revenue
$132.69M
TTM
+30.5%
YoY
Gross Margin
100%
TTM
+0.2%
YoY
Net Income
$91.94M
TTM
+154.0%
YoY
Operating Cash Flow
$-98.50M
TTM
+22.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 25.7 | 30.2 | 34.2 | 33.7 | 34.5 |
YoY Growth | +9.3% | +20.4% | +27.5% | +40.2% | +34.4% |
Cost of Revenue | 0.2 | 0.6 | 0.0 | 0.0 | 0.0 |
Gross Profit | 25.4 | 29.6 | 34.2 | 33.7 | 34.5 |
Selling, General & Administrative | 15.5 | 10.9 | 12.3 | 6.9 | 8.5 |
Other Operating Expenses | -0.1 | -0.3 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 42.2 | 34.1 | 19.8 | 18.7 | 23.2 |
Operating Income | -16.7 | -4.5 | 14.4 | 15.1 | 11.3 |
EBITDA | -13.5 | -1.5 | 15.0 | 15.6 | 11.8 |
Other Income / Expense | -0.0 | 81.6 | -9.0 | 38.8 | 3.4 |
Total Other Income / Expense | -13.3 | 68.5 | -25.0 | 24.2 | -11.9 |
Income Before Income Taxes | -30.0 | 63.9 | -10.6 | 39.2 | -0.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -30.0 | 63.9 | -10.6 | 39.2 | -0.6 |
Consolidated Net Income / Loss | -30.0 | 63.9 | -10.6 | 39.2 | -0.6 |
Net Income Attributable to Common Shareholders | -28.0 | 63.9 | -10.6 | 39.2 | -0.6 |
Basic EPS | -$1.00 | $2.00 | -$0.31 | $1.03 | -$0.01 |
Diluted EPS | -$1.00 | $1.94 | -$0.32 | $1.02 | -$0.01 |
Basic Shares Outstanding | 28.1M | 31.9M | 34.5M | 37.9M | 41.3M |
Diluted Shares Outstanding | 28.1M | 32.9M | 33.5M | 38.3M | 41.3M |